Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 1,540 nm fractional erbium-glass laser treatment combined with topical minoxidil significantly increased hair regrowth in alopecia areata patches compared to minoxidil alone, with response rates of 60% versus 16%, though the long-term effects remain unknown.

This study identified a recurrent mutation in the endothelin receptor type A associated with mandibulofacial dysostosis with alopecia, and proposed a mechanism involving increased ligand affinity due to structural changes.

This case report describes a rare instance where a young woman initially presented with macrophage activation syndrome as the first sign of systemic lupus erythematosus, and ultimately experienced multiorgan failure and death.

This study reviewed cases of Graham–Little-Piccardi–Lassueur syndrome and found that topical treatments were generally ineffective, while systemic therapies like prednisone, hydroxychloroquine, and isotretinoin led to partial hair regrowth and disease stabilization, highlighting the importance of early diagnosis and systemic therapy to improve outcomes.

This study found that combining microneedling with 5% minoxidil significantly improved hair appearance in androgenetic alopecia patients, with high patient satisfaction and no severe adverse events.

This article explores whether it's possible to stop the progression of male androgenetic alopecia without using antiandrogenic drugs and reports no new clinical findings.

This report highlights a case of a 35-year-old man developing alopecia universalis following alemtuzumab treatment for multiple sclerosis, suggesting potential links between this medication and drug-induced alopecia areata, though the genetic overlap of the conditions may also play a role.

Hair transplantation using micro- and minigraft megasessions is safe, effective, and provides natural results with high patient satisfaction.

This study found that photodynamic therapy with methyl 5-aminolevulinic acid was ineffective for treating alopecia totalis, even with microneedle rolling to enhance drug delivery.

In this study, AGA patients exhibited distinct lipidomic profiles and higher metabolic syndrome prevalence compared to controls, with certain lipids correlated to key AGA-related factors like DHT, PGD2, and TGF-β1.

This review concluded that low-dose oral minoxidil is an effective and well-tolerated treatment for male androgenetic alopecia, with significant hair density improvements and manageable side effects.

In this study, 70% of female androgenetic alopecia patients who did not respond to standard minoxidil experienced clinical improvement after switching to a propylene glycol-free, witch hazel-based 5% minoxidil sulfate solution, with the treatment also being well-tolerated.

In this study, researchers tested detachable microneedles with chitin derivatives in a mouse model of androgenic alopecia, finding them to induce greater hair regrowth than 5% minoxidil, while also positing these materials as safe and cost-effective alternatives for hair loss treatment.

This study reported that mycophenolate mofetil was effective in reducing signs and symptoms of active lichen planopilaris in 83% of patients who had failed multiple prior treatments.

In this study, researchers found that mogamulizumab-associated rashes and alopecia are common in patients treated for mycosis fungoides and Sézary syndrome and may be linked with a good treatment response.

This study found that combining low-fluence Q-switched Nd: YAG laser and intense pulsed light led to faster and more effective melasma treatment compared to using the laser alone, though recurrence still occurred.

This study found high patient satisfaction and quality of life in women with androgenetic alopecia using 5% minoxidil, although hair loss still influenced their social life and daily habits.

This study found that azathioprine may improve relapses and disability in patients with neuromyelitis optica spectrum disorder but is associated with higher adverse events compared to mycophenolate mofetil.

This dataset provides supplemental material for a study on long-term particulate matter exposure and androgenetic alopecia risk, including additional exposure data and sensitivity analyses, but reports no new clinical results.

The authors observed that the patterned melanoderma on the hairless scalp of fair-skinned Caucasian men with androgenic alopecia resembled similar patterns seen on facial skin.

AGA causes permanent hair loss; minoxidil helps men, finasteride helps men, minoxidil somewhat helps women, estrogens/antiandrogens lack evidence for women.

In this study, the combination of intradermal meso-solution and topical 5% minoxidil significantly increased hair re-growth in men with androgenetic alopecia compared to minoxidil alone.

GLP-1 and GLP-1/GIP agonists may increase the risk of hair loss.

This study analyzed randomized trials on low-level light therapy combined with minoxidil for androgenetic alopecia, reporting either superior or equivalent hair regrowth compared to minoxidil alone, with initial improvements tapering over time.

AGA patients have a lower quality of life than AA patients.

This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.

In a study on wound healing, researchers described injectable POEGMA‐DA hydrogels as a promising non-toxic alternative to traditional wound closure methods, showing effective tissue adhesion and enhanced regeneration of skin structures in a mouse model without significant inflammation.

This study found that the HairMax LaserComb® significantly increased hair density and was safe and well tolerated for treating androgenetic alopecia in men compared to a sham device.

ACTH promotes hair growth in mink, but α-MSH does not.

The conclusion is that managing hair loss conditions like FFA and melanoma requires individualized approaches, considering new findings and balancing treatment benefits with potential risks.